Key takeaways
- In FDA and HHS documents, TB-500 is a seven-amino-acid synthetic fragment; thymosin β4 is the 43-amino-acid protein. FDA staff say they are not the same substance.
- Human trials used the full protein, mostly as eye drops or a skin gel, with mixed results; none tested TB-500.
- Mass spectrometry tells them apart: 889.01 g/mol against about 4,963 g/mol.
- Both fall under WADA class S2.3, prohibited at all times.
01The difference in one table
As FDA and HHS describe it, TB-500 is a seven-amino-acid fragment copied from thymosin β4; thymosin β4 is the whole 43-amino-acid protein, and only the protein has been through human trials. The rows match our BPC-157 vs TB-500 comparison.
| Question | TB-500 | Thymosin β4 |
|---|---|---|
| What it is | Synthetic, N-acetylated heptapeptide Ac-LKKTETQ, matching positions 17–23 of thymosin β4; 889.01 g/mol | Naturally occurring 43-amino-acid protein; about 4,963 g/mol |
| Origin of the research | Its sequence was first tested, without the acetyl group, in a 2003 mouse study; FDA staff write that a veterinary preparation was marketed for equine and greyhound sports from 2011 | First isolated from calf thymus; later found in many cell types and in blood, saliva, tears and wound fluid |
| Proposed mechanisms (animal/cell) | Contains the protein’s actin-binding stretch; whether actin binding explains any effect “remains to be determined” | Binds and holds actin monomers, the building blocks of the cell’s internal scaffolding |
| Main models studied | Aged-mouse skin wounds with an unacetylated version (2003); cultured fibroblasts, where TB-500 did not change scratch closure (2024) | Mouse skin wounds; human trials of eye drops and skin gels |
| Human data | No published controlled study; one phase 1/2 trial recruiting since February 2026, no results | Phase 2 and 3 trials of eye drops and phase 2 trials of a skin gel, with mixed results; two published phase 1 safety studies of an intravenous form in healthy volunteers (2010, 2021); a randomised trial of a recombinant form in 96 people after a heart attack, published in 2025 |
| Evidence grade | T3/T4: animal and cell | T1/T2: small human trials, mixed results |
| FDA (Nov 2026) | Not approved. Compounding Category 2 from Sep 2023 to Apr 2026, now listed as a nomination withdrawn; named in HHS’s 2026 compounding enforcement-discretion policy | Not approved. Drugs@FDA lists no thymosin β4 product |
| WADA | Prohibited at all times, S2.3, named as an example | Prohibited at all times, S2.3 |
| Storage (as reported) | Reported stable below −20 °C, sealed, away from moisture and light, under nitrogen (as summarised by FDA staff) | Not covered by the sources on this page; see peptide storage |
02Is TB-500 the same molecule as thymosin β4?
No. FDA staff put it plainly: thymosin beta-4 and TB-500 “are not the same substance”, although websites often use the names interchangeably. TB-500 is seven amino acids long, with an acetyl group on the first one. Thymosin β4 is 43 amino acids long.
The acetyl group matters. FDA staff note that acetylation can change a peptide’s lifespan, folding and binding, which is why results with the unacetylated fragment “cannot be directly extrapolated” to TB-500. Results with the full protein are one step further away again.
What is sold under either name is a separate question. A French horse-racing laboratory that analysed products sold as TB500 and TB1000 reported in 2023 that their content was “not systematically consistent” with earlier descriptions of them.
03How a lab tells them apart
By mass. The fragment weighs 889.01 g/mol and the protein about 4,963 g/mol, so mass spectrometry separates them easily, and an identity result on a lab report should say which one the sample matches. A purity percentage cannot do this, because purity and identity are separate measurements. See mass spectrometry explained and how to read a COA.
04What the thymosin β4 trials found, and why it doesn’t transfer
The human evidence belongs to the full protein, and it is mixed.
Dry eye, phase 2 (n=72). A randomised, placebo-controlled trial of thymosin β4 eye drops missed both of its primary endpoints, eye discomfort and corneal staining, while several secondary measures differed from placebo. The authors observed no adverse events.
Neurotrophic keratopathy, phase 3 (n=18). A persistent defect in the cornea’s surface closed completely by four weeks in 6 of 10 people on the eye drops and 1 of 8 on placebo. That primary comparison did not reach statistical significance (p=0.0656). No significant adverse effects were observed. Three authors were employed by the company developing the product or its parent company.
Skin wounds, phase 2. Gel versions were tested in people with venous stasis ulcers, pressure ulcers and the blistering condition epidermolysis bullosa, and the registry carries posted results for these studies. The protein was also given intravenously to healthy volunteers in two published phase 1 studies, a synthetic form in 2010 (40 people) and a recombinant form in 2021 (84 people); both measured blood levels and adverse events. After a heart attack, two registered phase 2 trials of a recombinant form, given intravenously, are completed with no posted results, and a third has not started recruiting (ClinicalTrials.gov, 18 Nov 2026). A randomised, placebo-controlled, double-blind trial of a recombinant form in 96 people treated for an ST-elevation heart attack was published in 2025. It measured the size of the damaged area of heart muscle at 90 days, and three of its authors were employees of Beijing Northland Biotechnology, the sponsor of the registered recombinant trials.
None of these trials gave TB-500, and none was about sport. A result with a 43-amino-acid protein on the eye or skin says nothing direct about a seven-amino-acid acetylated fragment.
05What we don’t know
- Whether TB-500 does anything in people. No controlled human study has reported; a phase 1/2 trial registered in 2026 is recruiting.
- Whether TB-500 would cause harm in people. FDA says it “has not identified any human exposure data” and lacks information on whether it would.
- How the full protein behaves in people over longer periods. The two intravenous phase 1 studies were small and short, the published heart-attack trial followed people for 90 days, and two registered heart-attack trials have no posted results.
- Which molecule a given vial holds. Only a mass result on that lot’s report can say.
The full TB-500 profile, including safety reports and status in the US, UK and Australia, is on the TB-500 research guide. Sport: peptides and anti-doping.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.